Otyłość: badanie kliniczne

Gdzie prowadzone jest badanie

Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:

• Uniwersytet Radomski Rekrutuje
  RadomKontakt

Więcej badań w tych miastach:

• Radom

Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.

Cel badania

Opis z rejestru (w języku angielskim):

This study will evaluate four videolaryngoscopes used for intubation of extremely obese (class 3 obesity) patients scheduled for bariatric surgery. One hundred adult patients will be scheduled for an elective sleeve gastrectomy at the Mazowiecki Szpital Specjalistyczny in Radom, Poland. All patients will receive premedication with 300 mg pregabalin 30 minutes before the start of anaesthesia. An extended monitoring will be applied. This consists of ECG, IBP (invasive blood pressure), SpO2, TOF (train-of-four), entropy and volatile anaesthetic concentration. All patients will be placed in a ramped position (HELP - Head-elevated Laryngoscopy Position) and will be pre-oxygenated with FiO2 1.0 for three minutes prior to induction. A standardised local protocol of opioid-free anaesthesia for bariatric patients will be utilised. Prior to proper induction of anaesthesia, IV infusions of 1% lidocaine and dexmedetomidine 10 µg ml-1 will be started. This will be followed by induction with IV propofol (200 mg) and ketamine (50 mg). Rocuronium (100 mg) will be used as a neuromuscular blocking agent. Adequate neuromuscular block will be confirmed and controlled throughout the procedure with TOF Watch (Organon, Dublin, Ireland). A cuffed, size 8.0 tracheal tube with stylet (Sumi, Sulejówek, Poland) will be used for intubation. A single-use hyperangulated blade will be used in all studied devices. Correct placement of the tracheal tube will be confirmed by videolaryngoscopy, capnography and chest auscultation. All patients will be anaesthetised by experienced consultant anaesthetists with over 10 years of clinical practice after completion of specialist training. Furthermore, all anaesthetists participating in the study will be trained with all VLs used until they feel competent. Only two intubation attempts with a studied videolaryngoscope will be allowed. A single attempt will be limited to 60 seconds. A failure is defined as an attempt which lasted more than 60 seconds, when saturation dropped below 90%, after two unsuccessful attempts, when airway injury or bronchospasm occurred. A single-digit number will be allocated to each of the studied videolaryngoscopes: 1 for the C-MAC PM, 2 for the McGrath MAC, 3 for the VisionPro and 4 for the AceScope. A single sheet of paper containing printed number will be placed in an opaque envelope. Then they will be assigned to the participating anaesthetist by computer-generated randomization. The SPSS 29.0 software (IBM, Armonk, NY, USA) will be used for allocation. Furthermore, patients will be blinded to randomization.

Leczenie w badaniu

Kryteria udziału

Kryteria w języku angielskim, tak jak w rejestrze.

To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.

Inne badania: otyłość

RekrutujeFaza III

Cukrzyca: badanie fazy III leku AZD6234

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Badane leki: AZD6234+8

Miasta: Białystok, Elbląg, Gdynia, Katowice i 7 innych miastWiek: od 18 latSponsor: AstraZeneca

RekrutujeFaza III

Cukrzyca: badanie fazy III leku AZD6234

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Badane leki: AZD6234+8

Miasta: Białystok, Elbląg, Gdynia, Katowice i 7 innych miastWiek: od 18 latSponsor: AstraZeneca

RekrutujeFaza III

Badanie fazy III leku semaglutide

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Badane leki: semaglutide+2

Miasta: Białystok, Bydgoszcz, Bygdoszcz, Poznań i 3 inne miastaWiek: od 18 latSponsor: Novo Nordisk A/S

RekrutujeFaza III

Badanie fazy III leku ASC30

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Badane leki: ASC30

Miasta: Biała Podlaska, Bydgoszcz, Częstochowa, Gdańsk i 12 innych miastWiek: od 18 latSponsor: Ascletis Pharma (China) Co. Ltd.

RekrutujeFaza III

Cukrzyca: badanie fazy III leku ASC30

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Badane leki: ASC30

Miasta: Biała Podlaska, Bydgoszcz, Częstochowa, Gdańsk i 12 innych miastWiek: od 18 latSponsor: Ascletis Pharma (China) Co. Ltd.

Rekrutuje

Badanie kliniczne

MRI Assessment of Body Composition in Bariatric Surgery

Miasta: OlsztynWiek: od 18 latSponsor: University of Warmia and Mazury in Olsztyn

Wszystkie badania: otyłość